Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,019.13

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,019.13 72

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $1,019.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $13.2512/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887417031 CMS
ABBVIE INC. $6.4812/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297873 CMS
Lilly USA, LLC $6.1512/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954257 CMS
ABBVIE INC. $16.5811/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297871 CMS
Lilly USA, LLC $6.1611/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952635 CMS
Janssen Biotech, Inc. $1.8511/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934677 CMS
Regeneron Healthcare Solutions, Inc. $27.2311/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310077 CMS
ABBVIE INC. $14.9211/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297869 CMS
Novartis Pharmaceuticals Corporation $24.1810/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894049523 CMS
Lilly USA, LLC $5.7510/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954411 CMS
ABBVIE INC. $5.2210/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297867 CMS
GENZYME CORPORATION $22.6210/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002447 CMS
ABBVIE INC. $24.6010/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297865 CMS
Regeneron Healthcare Solutions, Inc. $24.5009/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310073 CMS
ABBVIE INC. $4.9109/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297863 CMS
Lilly USA, LLC $6.3709/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952287 CMS
ABBVIE INC. $11.1309/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297861 CMS
ABBVIE INC. $14.8409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297859 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.9308/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887417033 CMS
ABBVIE INC. $5.6208/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297857 CMS
GENZYME CORPORATION $29.3708/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002421 CMS
ABBVIE INC. $14.7408/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297855 CMS
ABBVIE INC. $16.6808/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297853 CMS
Janssen Biotech, Inc. $1.3308/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934703 CMS
Janssen Biotech, Inc. $23.0808/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934709 CMS
Lilly USA, LLC $6.3508/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954255 CMS
Lilly USA, LLC $5.2508/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917950217 CMS
Regeneron Healthcare Solutions, Inc. $23.2508/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310067 CMS
ABBVIE INC. $19.0407/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297851 CMS
GENZYME CORPORATION $23.2807/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002403 CMS
Janssen Biotech, Inc. $16.1507/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934687 CMS
ABBVIE INC. $10.8707/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297849 CMS
ABBVIE INC. $5.2407/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297847 CMS
ABBVIE INC. $5.1907/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297845 CMS
Lilly USA, LLC $19.2207/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954991 CMS
Janssen Biotech, Inc. $4.2306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934681 CMS
Janssen Biotech, Inc. $16.5406/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934693 CMS
Janssen Biotech, Inc. $20.1606/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934699 CMS
ABBVIE INC. $4.9106/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297843 CMS
ABBVIE INC. $5.6805/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297841 CMS
Lilly USA, LLC $12.3905/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952633 CMS
Janssen Biotech, Inc. $18.0905/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934715 CMS
Novartis Pharmaceuticals Corporation $21.1305/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894049519 CMS
ABBVIE INC. $7.9305/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297839 CMS
ABBVIE INC. $18.6405/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297837 CMS
ABBVIE INC. $19.1304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297835 CMS
GENZYME CORPORATION $23.6804/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002377 CMS
Lilly USA, LLC $5.2604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954409 CMS
Janssen Biotech, Inc. $17.4304/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934641 CMS
Janssen Biotech, Inc. $23.8504/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934647 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

284 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $6,709.50 12/30/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100763806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/17/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125501030
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 12/17/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125501032
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,764.57 12/12/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500580
Principal investigator 1 Incyte Corporation $1,121.30 12/11/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689271
Principal investigator 1 Incyte Corporation $2,080.00 12/11/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689583
Principal investigator 1 Incyte Corporation $22.70 12/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689471
Principal investigator 1 Incyte Corporation $45.80 12/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689479
Principal investigator 1 Janssen Research & Development, LLC $2,714.00 12/02/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020908
Principal investigator 1 Galderma Laboratories, L.P. $3,382.19 11/21/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156049725
Principal investigator 1 Incyte Corporation $2,266.00 11/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689485
Principal investigator 1 Incyte Corporation $1,230.50 11/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689487
Principal investigator 1 Incyte Corporation $24.70 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689473
Principal investigator 1 Incyte Corporation $22.90 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689475
Principal investigator 1 Incyte Corporation $0.30 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689477
Principal investigator 1 Incyte Corporation $4.90 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689481
Principal investigator 1 Incyte Corporation $8.20 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689483
Principal investigator 1 Incyte Corporation $8.20 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689493
Principal investigator 1 Incyte Corporation $8.20 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689495
Principal investigator 1 Incyte Corporation $8.20 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689497
Principal investigator 1 Incyte Corporation $16.20 11/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689517
Principal investigator 1 Janssen Research & Development, LLC $3,989.00 11/01/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 10/25/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498799
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,014.20 10/16/2024 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151794118
Principal investigator 1 Incyte Corporation $1,172.80 10/11/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689489
Principal investigator 1 Incyte Corporation $1,565.00 10/11/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689491
Principal investigator 1 Galderma Laboratories, L.P. $5,750.00 10/04/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156049455
Principal investigator 1 ABBVIE INC. $11,035.00 10/03/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1100745546
Principal investigator 1 Janssen Research & Development, LLC $1,460.00 10/03/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020910
Principal investigator 1 Galderma Laboratories, L.P. $551.95 09/19/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156049341
Principal investigator 1 Incyte Corporation $2,402.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689389
Principal investigator 1 Incyte Corporation $928.70 09/18/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689395
Principal investigator 1 Incyte Corporation $1,604.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689397
Principal investigator 1 ABBVIE INC. $11,040.00 09/04/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100740116
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689423
Principal investigator 1 Incyte Corporation $12.15 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689425
Principal investigator 1 Incyte Corporation $4.24 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689435
Principal investigator 1 Incyte Corporation $160.30 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689441
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689447
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689453
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689457
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689459
Principal investigator 1 Incyte Corporation $32.36 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689555
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689595
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689597
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689599
Principal investigator 1 Janssen Research & Development, LLC $2,581.00 09/02/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020920
Principal investigator 1 Incyte Corporation $1,477.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689387
Principal investigator 1 Incyte Corporation $2,266.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689499
Principal investigator 1 Incyte Corporation $1,619.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689519
Principal investigator 1 Incyte Corporation $793.10 08/14/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689557
Principal investigator 1 Galderma Laboratories, L.P. $2,441.21 08/08/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156049217
Principal investigator 1 Janssen Research & Development, LLC $1,772.00 08/05/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020918
Principal investigator 1 Dermavant Sciences, Inc. $165.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883809
Principal investigator 1 Dermavant Sciences, Inc. $165.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883813
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883817
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883821
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883826
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883830
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883834
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883838
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883842
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883847
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883851
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883855
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883859
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883864
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883868
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883872
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883876
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883880
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127883884
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127885201
Principal investigator 1 Dermavant Sciences, Inc. $35.00 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127885206
Principal investigator 1 Dermavant Sciences, Inc. $35.00 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127885210
Principal investigator 1 Dermavant Sciences, Inc. $165.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887201
Principal investigator 1 Dermavant Sciences, Inc. $165.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887205
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887209
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887213
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887217
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887222
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887226
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887230
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887234
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887239
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887243
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887247
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887252
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887256
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887260
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887264
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887269
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887273
Principal investigator 1 Dermavant Sciences, Inc. $177.22 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127887277
Principal investigator 1 Dermavant Sciences, Inc. $212.52 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127888588
Principal investigator 1 Dermavant Sciences, Inc. $35.00 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127888592
Principal investigator 1 Dermavant Sciences, Inc. $35.00 08/02/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127888596
Principal investigator 1 Incyte Corporation $0.93 08/01/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689413
Principal investigator 1 Incyte Corporation $16.18 08/01/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689415
Principal investigator 1 Incyte Corporation $49.36 08/01/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689417
Principal investigator 1 Incyte Corporation $186.81 08/01/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689419
Principal investigator 1 Incyte Corporation $125.95 08/01/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689513
Principal investigator 1 Amgen Inc. $1,968.00 07/25/2024 Non-covered Recipient Entity
DS RESEARCH
HORIZON P3 AD Monotherapy Induction No dispute reported 06/30/2026 1096310829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,851.95 07/25/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494465
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,170.50 07/23/2024 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151794116
Principal investigator 1 Dermavant Sciences, Inc. $177.22 07/20/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127878412
Principal investigator 1 Dermavant Sciences, Inc. $177.22 07/20/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127878416
Principal investigator 1 Dermavant Sciences, Inc. $212.52 07/20/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127878421
Principal investigator 1 Dermavant Sciences, Inc. $178.98 07/20/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127878425
Principal investigator 1 Incyte Corporation $2,080.00 07/10/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689269
Principal investigator 1 Incyte Corporation $1,565.00 07/10/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689391
Principal investigator 1 Incyte Corporation $1,672.00 07/10/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689393
Principal investigator 1 Incyte Corporation $876.80 07/10/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689469
Principal investigator 1 Amgen Inc. $750.00 07/09/2024 Non-covered Recipient Entity
DS RESEARCH
P2A DAX in Moderate-to-Severe AA No dispute reported 06/30/2026 1096312217
Principal investigator 1 Galderma Laboratories, L.P. $974.03 07/05/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048969
Principal investigator 1 Incyte Corporation $7.29 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689399
Principal investigator 1 Incyte Corporation $21.87 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689401
Principal investigator 1 Incyte Corporation $22.90 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689403
Principal investigator 1 Incyte Corporation $32.88 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689405
Principal investigator 1 Incyte Corporation $4.86 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689407
Principal investigator 1 Incyte Corporation $49.36 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689409
Principal investigator 1 Incyte Corporation $62.27 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689411
Principal investigator 1 Incyte Corporation $59.13 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689421
Principal investigator 1 Incyte Corporation $32.88 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689455
Principal investigator 1 Incyte Corporation $32.88 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689461
Principal investigator 1 Incyte Corporation $32.88 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689463
Principal investigator 1 Incyte Corporation $4.86 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689465
Principal investigator 1 Incyte Corporation $4.86 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689467
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689561
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689563
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689565
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689567
Principal investigator 1 Incyte Corporation $4.12 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689427
Principal investigator 1 Incyte Corporation $3.18 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689429
Principal investigator 1 Incyte Corporation $8.22 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689431
Principal investigator 1 Incyte Corporation $8.24 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689433
Principal investigator 1 Incyte Corporation $11.66 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689437
Principal investigator 1 Incyte Corporation $41.10 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689439
Principal investigator 1 Incyte Corporation $8.22 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689443
Principal investigator 1 Incyte Corporation $41.10 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689445
Principal investigator 1 Incyte Corporation $41.10 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689449
Principal investigator 1 Incyte Corporation $41.10 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689451
Principal investigator 1 Incyte Corporation $8.22 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689575
Principal investigator 1 Incyte Corporation $8.22 07/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689577
Principal investigator 1 Janssen Research & Development, LLC $1,593.00 06/27/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020912
Principal investigator 1 Incyte Corporation $2,402.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689263
Principal investigator 1 Incyte Corporation $1,565.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689267
Principal investigator 1 Incyte Corporation $1,672.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689337
Principal investigator 1 Incyte Corporation $1,477.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689347
Principal investigator 1 Incyte Corporation $474.20 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689381
Principal investigator 1 Incyte Corporation $2,402.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689383
Principal investigator 1 Incyte Corporation $1,604.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689515
Principal investigator 1 Incyte Corporation $1,983.00 06/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689559
Principal investigator 1 Incyte Corporation $32.36 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689349
Principal investigator 1 Incyte Corporation $0.62 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689351
Principal investigator 1 Incyte Corporation $22.90 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689357
Principal investigator 1 Incyte Corporation $59.13 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689359
Principal investigator 1 Incyte Corporation $98.72 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689361
Principal investigator 1 Incyte Corporation $2.79 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689363
Principal investigator 1 Incyte Corporation $97.08 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689365
Principal investigator 1 Incyte Corporation $62.27 06/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689521
Principal investigator 1 Janssen Research & Development, LLC $6,549.00 06/04/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1079020914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,543.43 06/03/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125492172
Principal investigator 1 Galderma Laboratories, L.P. $1,750.03 05/30/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048759
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,723.25 05/29/2024 Non-covered Recipient Entity
Dermatology Specialists Research
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1123476976
Principal investigator 1 Galderma Laboratories, L.P. $1,084.01 05/16/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048721
Principal investigator 1 Incyte Corporation $54.76 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689367
Principal investigator 1 Incyte Corporation $57.25 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689369
Principal investigator 1 Incyte Corporation $64.72 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689371
Principal investigator 1 Incyte Corporation $135.40 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689373
Principal investigator 1 Incyte Corporation $59.13 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689375
Principal investigator 1 Incyte Corporation $62.27 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689377
Principal investigator 1 Incyte Corporation $24.68 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689379
Principal investigator 1 Incyte Corporation $24.68 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689505
Principal investigator 1 Incyte Corporation $11.45 05/06/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689509
Principal investigator 1 Incyte Corporation $2,039.40 05/03/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689353
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,116.10 04/23/2024 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151794114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 04/23/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/23/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490157
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $755.00 04/23/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,148.33 04/23/2024 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490171
Principal investigator 1 GENZYME CORPORATION $7,246.99 04/22/2024 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1128709569
Principal investigator 1 GENZYME CORPORATION $675.00 04/22/2024 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1128709571
Principal investigator 1 Amgen Inc. $22,100.00 04/19/2024 Non-covered Recipient Entity
DS RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309173
Principal investigator 1 Galderma Laboratories, L.P. $451.33 04/11/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048595
Principal investigator 1 CSL Behring $872.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326024
Principal investigator 1 CSL Behring $1,238.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326026
Principal investigator 1 CSL Behring $235.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326028
Principal investigator 1 CSL Behring $5,000.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326030
Principal investigator 1 CSL Behring $342.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326032
Principal investigator 1 CSL Behring $1,492.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326034
Principal investigator 1 CSL Behring $359.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326036
Principal investigator 1 CSL Behring $3,497.00 04/05/2024 Non-covered Recipient Entity
Scott Health Services, LLC
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1142326038
Principal investigator 1 Eli Lilly and Company $3,097.00 04/05/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
Not supplied No dispute reported 06/30/2026 1137367351
Principal investigator 1 Incyte Corporation $1,477.00 04/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689355
Principal investigator 1 Incyte Corporation $1,181.60 04/05/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689385
Principal investigator 1 Incyte Corporation $45.80 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689339
Principal investigator 1 Incyte Corporation $91.60 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689341
Principal investigator 1 Incyte Corporation $0.93 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689343
Principal investigator 1 Incyte Corporation $1.24 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689345
Principal investigator 1 Incyte Corporation $32.36 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689501
Principal investigator 1 Incyte Corporation $32.36 04/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689503
Principal investigator 1 Acrotech Biopharma Inc. $40,387.50 03/28/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1147107936
Principal investigator 1 Galderma Laboratories, L.P. $2,084.36 03/21/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048521
Principal investigator 1 GENZYME CORPORATION $1,600.00 03/18/2024 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1128709567
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $3,074.47 03/18/2024 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1154868594
Principal investigator 1 Incyte Corporation $1,477.00 03/13/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689325
Principal investigator 1 Incyte Corporation $1,200.60 03/13/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689529
Principal investigator 1 Incyte Corporation $1,565.00 03/13/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689545
Principal investigator 1 Incyte Corporation $14.58 03/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689285
Principal investigator 1 Incyte Corporation $32.88 03/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689293
Principal investigator 1 Incyte Corporation $32.88 03/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689569
Principal investigator 1 Incyte Corporation $32.88 03/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689571
Principal investigator 1 Incyte Corporation $32.88 03/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689573
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 03/01/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875873
Principal investigator 1 Dermavant Sciences, Inc. $1,014.22 03/01/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875877
Principal investigator 1 Eli Lilly and Company $163.50 02/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1137357815
Principal investigator 1 Galderma Laboratories, L.P. $3,252.02 02/08/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis No dispute reported 06/30/2026 1156048357
Principal investigator 1 Incyte Corporation $1,983.00 02/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689257
Principal investigator 1 Incyte Corporation $1,477.00 02/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689327
Principal investigator 1 Incyte Corporation $1,815.80 02/07/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689329
Principal investigator 1 Incyte Corporation $0.62 02/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689273
Principal investigator 1 Incyte Corporation $22.90 02/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689291
Principal investigator 1 Incyte Corporation $32.36 02/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689295
Principal investigator 1 Incyte Corporation $98.72 02/02/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689315
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $19,576.60 02/01/2024 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151794122
Principal investigator 1 Acrotech Biopharma Inc. $3,490.00 01/25/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-301 No dispute reported 06/30/2026 1147107720
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $750.00 01/25/2024 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151794120
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $21,231.90 01/19/2024 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151794112
Principal investigator 1 Acrotech Biopharma Inc. $8,056.20 01/18/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-301 No dispute reported 06/30/2026 1147107704
Principal investigator 2 Arcutis Biotherapeutics, Inc. $400.00 01/15/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031688
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 01/13/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127874747
Principal investigator 1 Eli Lilly and Company $40,335.75 01/09/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1137366319
Principal investigator 1 Acrotech Biopharma Inc. $1,550.00 01/04/2024 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-301 No dispute reported 06/30/2026 1147107638
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689259
Principal investigator 1 Incyte Corporation $123.40 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689261
Principal investigator 1 Incyte Corporation $19.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689265
Principal investigator 1 Incyte Corporation $2.17 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689275
Principal investigator 1 Incyte Corporation $1.86 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689277
Principal investigator 1 Incyte Corporation $2.79 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689279
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689281
Principal investigator 1 Incyte Corporation $6.51 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689283
Principal investigator 1 Incyte Corporation $21.87 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689287
Principal investigator 1 Incyte Corporation $19.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689289
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689297
Principal investigator 1 Incyte Corporation $45.80 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689299
Principal investigator 1 Incyte Corporation $51.03 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689301
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689303
Principal investigator 1 Incyte Corporation $59.13 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689305
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689307
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689309
Principal investigator 1 Incyte Corporation $74.04 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689311
Principal investigator 1 Incyte Corporation $80.90 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689313
Principal investigator 1 Incyte Corporation $123.40 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689317
Principal investigator 1 Incyte Corporation $226.52 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689319
Principal investigator 1 Incyte Corporation $206.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689321
Principal investigator 1 Incyte Corporation $311.35 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689323
Principal investigator 1 Incyte Corporation $24.66 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689331
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689333
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689335
Principal investigator 1 Incyte Corporation $9.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689507
Principal investigator 1 Incyte Corporation $135.40 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689511
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689523
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689525
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689527
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689531
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689533
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689535
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689537
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689539
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689541
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689543
Principal investigator 1 Incyte Corporation $2.48 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689547
Principal investigator 1 Incyte Corporation $24.66 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689549
Principal investigator 1 Incyte Corporation $24.66 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689551
Principal investigator 1 Incyte Corporation $24.66 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689553
Principal investigator 1 Incyte Corporation $103.05 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689579
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689581
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689585
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689587
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689589
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689591
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134689593
Principal investigator 1 Amgen Inc. $11,057.93 01/03/2024 Non-covered Recipient Entity
DS RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309175